10066539EMBRACE - Early detection of Brain Cancer using a novel spectroscopic liquid biopsy enabling timely detection and diagnosis for patient benefitClosedEU-FundedHorizon Europe GuaranteeDxcover is a clinical stage diagnostics company, dedicated to delivering innovative early cancer diagnostics to the clinic. Using our platform technology, we will provide the world’s first game-changing blood test for brain cancer detection (Dxcover Brain) that fits seamlessly into current standard-of-care pathway. Brain cancer reduces life expectancy by over 20 years on average, a statistic that is largely attributed to its late detection. The diagnostic pathway is highly inefficient, as currently only ~2% of patients referred for imaging actually have brain cancer. Dxcover’s unique technology uses infrared light to detect signals from the tumour and signals from the body’s response to the tumour. Currently validated in >3000 patient samples across multiple clinical studies, we provides a simple workflow, and a fast and affordable solution for early cancer detection. EIC funding will allow Dxcover to obtain CE-IVDR approval, target the European market and reach the patient faster.